MedTrace Logo

An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)

NCT04941768 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2025-11-28

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to expand knowledge on the effectiveness of Avelumab intravenous infusion in combination with Axitinib as the first-line therapy in participants with advanced renal-cell carcinoma (aRCC) in addition to the safety and tolerability under routine conditions of daily clinical practice.

Conditions

  • Carcinoma, Renal Cell

Sponsors & Collaborators

  • Merck Healthcare Germany GmbH, an affiliate of Merck KGaA, Darmstadt, Germany

    collaborator UNKNOWN

  • Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Medical Responsible · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-09
Primary Completion
2024-08-08
Completion
2025-04-30

Countries

  • Belgium
  • Germany
  • Greece
  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04941768 on ClinicalTrials.gov